Réactifs et instruments pour l'immunologie, la biologie cellulaire et la biologie moléculaire.
 
> 5-Fluorouracil [51-21-8]

5-Fluorouracil [51-21-8]

Imprimer Imprimer
Identifiez-vous

Référence HY-90006-1g

Conditionnement : 1g

Marque : MedChemExpress

Contactez votre distributeur local :


Téléphone : +1 850 650 7790

5-fluorouracile (5-FU) est un analogue de l'uracile et un agentpuissant antitumoral. 5-fluorouracile affecte la synthèse de pyrimidine en inhibant la thymidylate synthétase épuisant ainsi les pools de dTTP intracellulaires. 5-fluorouracile induit l'apoptose et peut être utilisé comme sensibilisateur chimique. 5-fluorouracile inhibe également HIV.

5-Fluorouracil (5-FU) ist ein Analogon von Uracil und ein wirksames Antitumormittel. 5-Fluorouracil beeinflusst die pyrimidine synthesis, indem es die Thymidylatsynthetase hemmt und somit die intrazellulären dTTP-Pools verarmt. 5-Fluorouracil induziert apoptosis und kann als chemischer Sensibilisator verwendet werden. 5-Fluorouracil hemmt auch HIV. 5-Fluorouracil (5-FU) could disrupt the exosome specific rRNA processing.

5-Fluorouracil (5-FU) is an analogue of uracil and a potent antitumor agent. 5-Fluorouracil affects pyrimidine synthesis by inhibiting thymidylate synthetase thus depleting intracellular dTTP pools. 5-Fluorouracil induces apoptosis and can be used as a chemical sensitizer. 5-Fluorouracil also inhibits HIV.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

5-Fluorouracil Chemical Structure

5-Fluorouracil Chemical Structure

CAS No. : 51-21-8

This product is a controlled substance and not for sale in your territory.

Based on 219 publication(s) in Google Scholar

Other Forms of 5-Fluorouracil:

  • 5-Fluorouracil-d Obtenir un devis
  • 5-Fluorouracil-13C,15N2 Obtenir un devis
  • 5-Fluorouracil-15N2 Obtenir un devis
  • 5-Fluorouracil-13C4,15N2 Obtenir un devis
  • 5-Fluorouracil (Standard) Obtenir un devis

    5-Fluorouracil purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2022 Oct;9(30):e2200717.  [Abstract]

    A transient upregulation and subsequent downregulation of RSK2 phosphorylation at Thr577 by 5-Fluorouracil (5-FU), which is accompanied by the accumulation of γ‐H2AX phosphorylation in a time‐dependent manner.

    5-Fluorouracil purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2022 Oct;9(30):e2200717.  [Abstract]

    In Hct116 cells, the inhibitory effects of 5-Fluorouracil (5-FU on cell growth at 2-10 μM are significantly enhanced by RSK2 or PAK4 inhibitors in short‐term and long‐term assays.

    5-Fluorouracil purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2022 Aug;10(8):e004006.  [Abstract]

    Hep3B and Huh7 cells are treated with 5-Fluorouracil for 24 h, then the cellular protein expression of p-IRF3 and pP65 is detected by immunoblotting.

    5-Fluorouracil purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2022 Apr 11;18(7):2882-2897.  [Abstract]

    Representative immunoblots assessing apoptosis induced by 5-Fluorouracil (5-FU) in immortalized human ventricular myocytes (AC16).

    5-Fluorouracil purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2021 Nov;8(21):e2101936.  [Abstract]

    ER stress pathways in HCT116/5-FU cells treated with 5-Fluorouracil (5-FU; 60 μM) with SR140333 or Aprepitant either as single agents or in combination at 24 h.

    5-Fluorouracil purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2021 Nov;8(21):e2101936.  [Abstract]

    Cell viability upon treatment with 5-Fluorouracil (5-FU; 60 μM), SR140333, or Aprepitant either as single agents or in combination at 24 h in HCT116 cells.

    5-Fluorouracil purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2021 Nov;8(21):e2101936.  [Abstract]

    Western blotting of drug-resistant proteins in HCT116/5-FU cells treated with 5-Fluorouracil (5-FU; 80 μM) at 48 h.

    5-Fluorouracil purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2021 Nov;8(21):e2101936.  [Abstract]

    The combination of SR140333 or aprepitant and 5-Fluorouracil (5-FU; mg/kg) decreases the expression levels of ABCC1, ABCG2, p-ERK1/2, and c-Myc and increased those of p-PERK, ATF4, and CHOP compared with 5-FU treatment alone.

    5-Fluorouracil purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2021 Apr 30;40(1):150.  [Abstract]

    Inhibition rate of proliferation in pcDNA3.1 or ZBTB28 transfected cells treated with gradient concentration of 5-FU for 72 hours.

    5-Fluorouracil purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2021 Jul 20;118(29):e2026813118.  [Abstract]

    Overexpression of RMRP impairs 5-FU–induced p53 activation determined by RT-qPCR.

    5-Fluorouracil purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2021 Jul 20;118(29):e2026813118.  [Abstract]

    Overexpression of RMRP impairs 5-FU-induced p53 activation determined by IB.

    5-Fluorouracil purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2021 Apr 1;12(4):338.  [Abstract]

    SW620, CACO2, and HCT15 cells are treated with different concentrations of UTD1 and 5-Fluorouracil (5-FU), and cell viability is measured by CCK-8.

    5-Fluorouracil purchased from MedChemExpress. Usage Cited in: Int J Biochem Cell Biol. 2018 Mar;96:9-19.  [Abstract]

    Hep3B cells are treated with 2 μmol Shikonin, 5-FU, BSNQ or OSNQ for different times (3, 6, 12 and 24 h), and stained with Annexin V and PI. The apoptotic cells are detected by fluorescence microscopy and quantified as percentages.

    5-Fluorouracil purchased from MedChemExpress. Usage Cited in: J Cell Biochem. 2018 Nov 28.  [Abstract]

    The expressions of apoptotic-related proteins, cleaved-PARP, caspase-3-active are detected in control, STAT5A, STAT5A+5-Fu, DEC2+5-Fu, DEC2/STAT5A+5-Fu of MKN45 and MKN28 cell lines using Western blot analysis.

    5-Fluorouracil purchased from MedChemExpress. Usage Cited in: J Cell Biochem. 2018 Nov 28.  [Abstract]

    MKN45 and MKN28 cells transfected with empty and DEC2 vectors are incubated in control medium or 5-Fu of 10 μM for 48 hours, then proliferation ratio of these cells is figured by EdU incorporation assay.

    5-Fluorouracil purchased from MedChemExpress. Usage Cited in: J Cell Biochem. 2018 Nov 28.  [Abstract]

    The expressions of apoptotic-related proteins, cleaved-PARP, caspase-3-active and survivin are detected in MKN45, MKN45+5-Fu, MKN45-EV, MKN45-DEC2, MKN45-DEC2+5-Fu, MKN28, MKN28+5-Fu, MKN28-EV, MKN28-DEC2, MKN28-DEC2+5-Fu cells using Western blot analysis.

    5-Fluorouracil purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2018 Jun 27;501(3):636-642.  [Abstract]

    Immunoblot analysis of the expression levels of BCL-2 and BAX after treatment of HCT116 TP53-/- cells with 20 μM 5-FU and 1.25 μM DHA alone or in combination for 48 h. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) served as a loading control.

    5-Fluorouracil purchased from MedChemExpress. Usage Cited in: Med Sci Monit. 2018 Sep 21;24:6666-6672.  [Abstract]

    Expression of protein of OPA1, Mfn1, Mfn2, Drp1 and Fis1 in heart mitochondria of rats treated with different 5-FU concentrations. The control group is intraperitonealled injection with same amount of physiological saline.

    5-Fluorouracil purchased from MedChemExpress. Usage Cited in: Tumour Biol. 2016 Jul;37(7):8811-24.  [Abstract]

    Assays for autophagy activity. Immunoblot analysis for LC3B. Compared with the Lenti-NC cells, the Lenti-CD44v6 cells display a higher intensity of autophagy flux but not steady-state levels when treated with 5-FU (*P<0.001).

    Voir tous les produits spécifiques à Isoform HIV:

    Voir toutes les isoformes
    HIV HIV-1 HIV-2
    Description

    5-Fluorouracil (5-FU) is an analogue of uracil and a potent antitumor agent. 5-Fluorouracil affects pyrimidine synthesis by inhibiting thymidylate synthetase thus depleting intracellular dTTP pools. 5-Fluorouracil induces apoptosis and can be used as a chemical sensitizer[1][2]. 5-Fluorouracil also inhibits HIV[3].

    IC50 & Target[1][6]

    HIV

     

    In Vitro

    5-Fluorouracil (5-Fu) and NSC 123127 (Dox) show synergistic anticancer efficacy. The IC50 value of 5-Fu/Dox-DNM toward human breast cancer (MDA-MB-231) cells is 0.25 μg/mL, presenting an 11.2-fold and 6.1-fold increase in cytotoxicity compared to Dox-DNM and 5-Fu-DNM, respectively[1]. In 5-fluorouracil (5-FU) and CDDP treated NFBD1-inhibited NPC cells, the NFBD1 expression in NPC CNE1 cell lines is depleted using lentivirus-mediated short hairpin RNA, and the sensitivity of these cells is elevated. NFBD1 knockdown leads to an obvious induction of apoptosis in CDDP- or 5-FU-treated CNE1 cells[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    5-Fluorouracil Related Antibodies
    In Vivo

    5-Fluorouracil (23 mg/kg, 3 times/week) for 14 days, induces accelerated gastrointestinal transit associated with acute intestinal inflammation at day 3 after the start of treatment, which may have led to persistent changes in the ENS observed after days 7 and 14 of treatment contributing to delayed gastrointestinal transit and colonic dysmotility[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Essai clinique
    Masse moléculaire

    130.08

    Formule

    C4H3FN2O2
    CAS No.

    51-21-8
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    O=C(N1)NC=C(F)C1=O
    Structure Classification
    • Others
    Initial Source
    • Endogenous metabolite
    Livraison

    Room temperature in continental US; may vary elsewhere.
    Stockage

    4°C, protect from light

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    Solvant et solubilité
    In Vitro: 

    DMSO : 50 mg/mL (384.38 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    1 M Ammonium hydroxide : 50 mg/mL (384.38 mM; Need ultrasonic)

    H2O : 10 mg/mL (76.88 mM; ultrasonic and warming and heat to 60°C)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 7.6876 mL 38.4379 mL 76.8758 mL
    5 mM 1.5375 mL 7.6876 mL 15.3752 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Calculateur de molarité

    • Calculateur de dilution

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (19.22 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (19.22 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  PBS

      Solubility: 25 mg/mL (192.19 mM); Clear solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Pureté et documentation

    Purity: 99.99%

    COA (254 KB) RP-HPLC (258 KB) Elemental Analysis Report (113 KB)

    Instruction de manipulation (2659 KB)
    Références

    • [1]. Han R, et al. Amphiphilic dendritic nanomicelle-mediated co-delivery of 5-fluorouracil and NSC 123127 for enhanced therapeutic efficacy. J Drug Target. 2016 Jun 29:1-28. [Epub ahead of print]  [Content Brief]

      [2]. Zeng Q, et al. Knockdown of NFBD1/MDC1 enhances chemosensitivity to NSC 119875 or 5-fluorouracil in nasopharyngeal carcinoma CNE1 cells. Mol Cell Biochem. 2016 Jul;418(1-2):137-46.  [Content Brief]

      [3]. Jones DH, et al. Ten-Year and Beyond Follow-up After Treatment With Highly Purified Liquid-Injectable Silicone for HIV-Associated Facial Lipoatrophy: A Report of 164 Patients. Dermatol Surg. 2019 Jul;45(7):941-948.  [Content Brief]

      [4]. McQuade RM, et al. Gastrointestinal dysfunction and enteric neurotoxicity following treatment with anticancer chemotherapeutic agent 5-fluorouracil. Neurogastroenterol Motil. 2016 Jun 28.  [Content Brief]

      [5]. Yin L, et al. Antitumor effects of oncolytic herpes simplex virus type 2 against colorectal cancer in vitro and in vivo. Ther Clin Risk Manag. 2017 Feb 7;13:117-130.  [Content Brief]

      [6]. Snyder SM, et al. Initial Experience with Topical Fluorouracil for Treatment of HIV-Associated Anal Intraepithelial Neoplasia. J Int Assoc Physicians AIDS Care (Chic). 2011;10(2):83-88.  [Content Brief]

      [7]. Pek Yee Lum, et al. Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. Cell. 2004 Jan 9;116(1):121-37.  [Content Brief]

    Administration animale
    [2]

    Mice receive intraperitoneal injections of 5-FU (23 mg/kg), 3 times a week via a 26 gauge needle. 5-FU is dissolved in 100% dimethyl sulfoxide (DMSO) to make 1 M/L stock solution refrigerated at −20°C. The stock is then defrosted and diluted with sterile water to make 0.1 M/L (10% DMSO) solutions for intraperitoneal injections. The dose of 5-FU is calculated to be equivalent to standard human dose per body surface area. The low doses of 5-FU (10-40 mg/kg) have been shown to have antitumor efficacy in mouse models of cancer. Sham-treated mice received 10% DMSO in sterile water via intraperitoneal injection three times a week via a 26 gauge needle. The injected volumes are calculated to the body weight; the maximum volume does not exceed 200 μL per injection. Mice are euthanized via cervical dislocation at 3 (2 treatments), 7 (3 treatments), and 14 (6 treatments) days after the first injection and colon is collected for in vitro experiments.

    MCE n'a pas confirmé de manière indépendante l'exactitude de ces méthodes. Ils sont pour référence seulement.
    Références

    • [1]. Han R, et al. Amphiphilic dendritic nanomicelle-mediated co-delivery of 5-fluorouracil and NSC 123127 for enhanced therapeutic efficacy. J Drug Target. 2016 Jun 29:1-28. [Epub ahead of print]  [Content Brief]

      [2]. Zeng Q, et al. Knockdown of NFBD1/MDC1 enhances chemosensitivity to NSC 119875 or 5-fluorouracil in nasopharyngeal carcinoma CNE1 cells. Mol Cell Biochem. 2016 Jul;418(1-2):137-46.  [Content Brief]

      [3]. Jones DH, et al. Ten-Year and Beyond Follow-up After Treatment With Highly Purified Liquid-Injectable Silicone for HIV-Associated Facial Lipoatrophy: A Report of 164 Patients. Dermatol Surg. 2019 Jul;45(7):941-948.  [Content Brief]

      [4]. McQuade RM, et al. Gastrointestinal dysfunction and enteric neurotoxicity following treatment with anticancer chemotherapeutic agent 5-fluorouracil. Neurogastroenterol Motil. 2016 Jun 28.  [Content Brief]

      [5]. Yin L, et al. Antitumor effects of oncolytic herpes simplex virus type 2 against colorectal cancer in vitro and in vivo. Ther Clin Risk Manag. 2017 Feb 7;13:117-130.  [Content Brief]

      [6]. Snyder SM, et al. Initial Experience with Topical Fluorouracil for Treatment of HIV-Associated Anal Intraepithelial Neoplasia. J Int Assoc Physicians AIDS Care (Chic). 2011;10(2):83-88.  [Content Brief]

      [7]. Pek Yee Lum, et al. Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. Cell. 2004 Jan 9;116(1):121-37.  [Content Brief]

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    H2O / DMSO / 1 M Ammonium hydroxide 1 mM 7.6876 mL 38.4379 mL 76.8758 mL 192.1894 mL
    5 mM 1.5375 mL 7.6876 mL 15.3752 mL 38.4379 mL
    10 mM 0.7688 mL 3.8438 mL 7.6876 mL 19.2189 mL
    15 mM 0.5125 mL 2.5625 mL 5.1251 mL 12.8126 mL
    20 mM 0.3844 mL 1.9219 mL 3.8438 mL 9.6095 mL
    25 mM 0.3075 mL 1.5375 mL 3.0750 mL 7.6876 mL
    30 mM 0.2563 mL 1.2813 mL 2.5625 mL 6.4063 mL
    40 mM 0.1922 mL 0.9609 mL 1.9219 mL 4.8047 mL
    50 mM 0.1538 mL 0.7688 mL 1.5375 mL 3.8438 mL
    60 mM 0.1281 mL 0.6406 mL 1.2813 mL 3.2032 mL
    DMSO / 1 M Ammonium hydroxide 80 mM 0.0961 mL 0.4805 mL 0.9609 mL 2.4024 mL
    100 mM 0.0769 mL 0.3844 mL 0.7688 mL 1.9219 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    5-Fluorouracil Related Classifications

    Help & FAQs

    Keywords:

    5-Fluorouracil51-21-85-FUNucleoside Antimetabolite/AnalogHIVApoptosisEndogenous MetaboliteHuman immunodeficiency virusInhibitorinhibitorinhibit

    Vous serez peut-être également intéressé par les produits suivants :



    Référence
    Description
    Cond.
    Prix HT
    B1089-5mg
    CMX001 [444805-28-1]
     5mg